Login to Your Account

DODAC members size up suicide risk, side with brodalumab

By Marie Powers
News Editor

Tuesday, July 19, 2016

In a solid win for Valeant Pharmaceuticals International Inc., the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 18-0 in favor of approving the BLA for brodalumab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription